Q3 2023 EPS Estimates for IQVIA Holdings Inc. Increased by Zacks Research (NYSE:IQV)

IQVIA Holdings Inc. (NYSE:IQV – Get Rating) – Equities researchers at Zacks Research lifted their Q3 2023 earnings per share (EPS) estimates for shares of IQVIA in a report issued on Monday, May 22nd. Zacks Research analyst S. Dey now expects that the medical research company will earn $2.35 per share for the quarter, up from their prior forecast of $2.33. The consensus estimate for IQVIA’s current full-year earnings is $9.28 per share. Zacks Research also issued estimates for IQVIA’s FY2023 earnings at $9.21 EPS, Q1 2024 earnings at $2.31 EPS and Q1 2025 earnings at $2.51 EPS.

Several other research firms have also issued reports on IQV. Guggenheim dropped their price target on IQVIA from $266.00 to $258.00 in a research report on Friday, April 28th. Wells Fargo & Company dropped their price target on IQVIA from $235.00 to $220.00 in a research report on Monday, May 1st. StockNews.com started coverage on IQVIA in a research report on Thursday, May 18th. They set a “hold” rating on the stock. Credit Suisse Group reissued an “outperform” rating and set a $265.00 price target on shares of IQVIA in a research report on Monday, February 13th. Finally, Barclays lowered their price objective on IQVIA from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 4th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $253.25.

IQVIA Stock Performance

IQV stock opened at $197.47 on Thursday. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 1.99. The firm has a market cap of $36.64 billion, a P/E ratio of 35.52, a P/E/G ratio of 2.03 and a beta of 1.39. IQVIA has a 12-month low of $165.75 and a 12-month high of $249.11. The stock’s 50 day simple moving average is $194.16 and its 200 day simple moving average is $208.10.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of IQV. Old North State Trust LLC grew its stake in shares of IQVIA by 342.2% in the first quarter. Old North State Trust LLC now owns 597 shares of the medical research company’s stock worth $27,000 after purchasing an additional 462 shares in the last quarter. Hanson & Doremus Investment Management lifted its holdings in shares of IQVIA by 300.0% in the first quarter. Hanson & Doremus Investment Management now owns 144 shares of the medical research company’s stock valued at $29,000 after buying an additional 108 shares during the period. Glassy Mountain Advisors Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at $31,000. Spire Wealth Management lifted its holdings in shares of IQVIA by 40.3% in the fourth quarter. Spire Wealth Management now owns 167 shares of the medical research company’s stock valued at $34,000 after buying an additional 48 shares during the period. Finally, AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the first quarter valued at $36,000. Institutional investors own 86.20% of the company’s stock.

About IQVIA

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.